- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03776474
Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children (IgG4)
The study objectives are :
Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.
Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Immunoglobulin E (IgE) mediated allergies to cow's milk and hen's egg affects 2-3% and 0.5-2.5% of children respectively. These allergies expose to the risk of immediate anaphylactic reaction that may be life-threatening. Approximately 70-80% of children with IgE mediated allergies to cow's milk and hen's egg will tolerate these foods by the age of 6 years. However, in the absence of reliable biomarker of tolerance, to determine whether oral tolerance is obtained, it is recommended to perform an oral food challenge (OFC) in a hospital setting. This procedure is expensive, time consuming, and carries the risk of anaphylactic reactions. Many studies have tried to find predictive markers of reactivity during the OFC. Improving the prediction of the response to OFC would be very useful to better select children in whom an OFC can be performed without risk to confirm the acquisition of tolerance.
For instance, serum specific IgE positive values beyond which 95% of patients would have an allergic reaction have been proposed. These values are highly variable from one study to another because of methodological differences and heterogeneity of populations, and cannot be used in clinical practice.
The regular dosage of serum specific IgE and its evolution over time is used in clinical practice to predict a possible persistence of IgE mediated food allergy. Indeed, an initial high rate and/or elevation of specific IgE levels may be predictive of a persistent allergy, while initial low rates and a decrease in specific IgE may predict tolerance. When tolerance develops, there is a decrease in specific IgE levels, however, even if tolerance is obtained, they can remain positive at pathological levels.
During continuous exposure to an allergen, the specific immunoglobulin G4 (IgG4) response is physiological. Oral immunotherapy studies in food allergies showed an elevation of specific IgG4, associated with an elevation in the number of regulatory T lymphocytes (LTreg) and the production of interleukin (IL)-10. The development of spontaneous oral tolerance, without the intervention of immunotherapy, also seems to involve IgG4. In a prospective follow-up of a cohort of children with an IgE-mediated cow's milk allergy, the elevation of specific IgG4 was observed in those who cure of their allergy, with rates higher than those observed in children whose allergy persists. In children with cow's milk and/or egg allergies, a low concentration of specific (IgG4 of B-Lactoglobulin or ovalbumin is associated with the need for a more prolonged exclusion diet. The balance between specific IgE and IgG4 therefore appears to be important in the development of tolerance and may reflect the balance between effector T cells and LTreg. However, the normal serum levels of IgG4 to cow's milk and hen's egg are unknown.
A recently published study of Doctor Guillaume Lezmi and Professor Karine Adel-Patient shows that children with an IgE-mediated allergy to cow's milk protein and those who outgrew this allergy, have distinct plasma metabolomic signature. This suggests that plasma metabolomic analysis may be a useful too to differentiate children with a persistent cow's milk protein allergy from those who acquired tolerance to cow's milk. If confirmed, the metabolic signature may be useful to better identify children to whom an oral food challenge with cow's milk protein could be propose. These results need to be confirmed in a larger population and in other food allergies.
The study objectives are :
Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.
Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).
Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Guillaume Lezmi, MD, PhD
- Phone Number: +33 1 44 49 48 38
- Email: guillaume.lezmi@aphp.fr
Study Locations
-
-
-
Paris, France, 75015
- Recruiting
- Hôpital Necker Enfants Malades
-
Contact:
- Guillaume Lezmi, MD, PhD
- Phone Number: +33 1 44 49 48 38
- Email: guillaume.lezmi@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Minors aged 0 to 18
- In consultation or hospitalized for an oral food challenge for milk or eggs
- To undergo a blood test
Exclusion Criteria:
Minors with immune deficiency, chronic inflammatory disease or immunosuppressive or immunomodulator treatment
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Allergic
Minors allergic to cow's milk and/or eggs
|
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
|
Non-allergic
Minors without history of allergy to cow's milk and/or eggs
|
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
|
Acquired tolerance
Minors formerly allergic to cow's milk and/or eggs
|
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of casein-specific immunoglobulin G4 and egg-specific immunoglobulin G4
Time Frame: Day 0
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of casein-specific immunoglobulin E and egg-specific immunoglobulin E
Time Frame: Day 0
|
Day 0
|
Total immunoglobulin E plasma concentration
Time Frame: Day 0
|
Day 0
|
Plasma concentration of casein-specific immunoglobulin G4 / plasma concentration of casein-specific immunoglobulin E ratio
Time Frame: Day 0
|
Day 0
|
Plasma concentration of egg-specific immunoglobulin G4 / plasma concentration of egg-specific immunoglobulin E ratio
Time Frame: Day 0
|
Day 0
|
Plasma concentration of casein-specific immunoglobulin G4 / total immunoglobulin E plasma concentration ratio
Time Frame: Day 0
|
Day 0
|
Plasma concentration of egg-specific immunoglobulin G4 / total immunoglobulin E plasma concentration ratio
Time Frame: Day 0
|
Day 0
|
Plasma metabolomic analysis
Time Frame: Day 0
|
Day 0
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP180057
- 2018-A01972-53 (Registry Identifier: ID RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Allergy in Children
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Stanford UniversityRecruitingFood Allergy | Food Allergy in ChildrenUnited States
-
Rhode Island HospitalCompletedFood Allergy in Children
-
Children's National Research InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Northwestern... and other collaboratorsRecruiting
-
Federico II UniversityRecruiting
-
Rhode Island HospitalVirtually Better, Inc.CompletedFood Allergy in Children
-
Chinese University of Hong KongRecruiting
-
Central Hospital, Nancy, FranceNot yet recruitingFood Allergy in ChildrenFrance
Clinical Trials on Blood collection
-
University of South AlabamaRecruitingBurns | TraumaUnited States
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruiting
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitUnknown
-
Skane University HospitalLund University; Region SkaneActive, not recruitingSepsis | Critical Illness | Covid19 | Trauma | Influenza | Cardiac ArrestSweden
-
University of FloridaNational Institutes of Health (NIH); DiaCarta, Inc.Completed
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
Sir Run Run Shaw HospitalNot yet recruitingCatheter ComplicationsChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingSeminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8Canada, United States, Guam
-
Assistance Publique - Hôpitaux de ParisFonds IMMUNOVCompleted
-
GlaxoSmithKlineCompleted